SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Multiple Sclerosis
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Montalban, X.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Montalban, X.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Overview of European pilot study of interferon b-1b in primary progressive multiple sclerosis

Xavier Montalban

University Hospital Vall d'Hebron, Unitat de Neuroimmunologia Clinica, E-08035, Barcelona, Spain, xmontalban{at}.vhebron.net

This short monograph describes a trial of interferon b-1b in patients with primary progressive multiple sclerosis (PPMS) or transitional MS. Designed as a randomized, placebo -controlled pilot, the trial randomly placed 73 eligible patients into two groups, placebo or interferon b-1b 8 MIU given subcutaneo usly every other day for two years. Significant differences favouring interferon b-1b in the MSFC score, T2 lesion volume and T1 lesion volume at 24 months were observed. Further study of interferon b-1b therapy in PPMS patients is warranted.

Key Words: primary progressive MS • interferon ß-1b • MRI • EDSS • MSFC

Multiple Sclerosis, Vol. 10, No. 3 suppl, S62-S64 (2004)
DOI: 10.1191/1352458504ms1033oa
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 Mult SclerHome page
L. Bosma, J. Kragt, L Brieva, Z Khaleeli, X Montalban, C. Polman, A. Thompson, M Tintore, and B. Uitdehaag
The search for responsive clinical endpoints in primary progressive multiple sclerosis
Multiple Sclerosis, June 1, 2009; 15(6): 715 - 720.
[Abstract] [PDF]

Home page
 Mult SclerHome page
N. Tellez, M. Comabella, E v. Julia, J. Rio, M a. Tintore, L. Brieva, C. Nos, and X. Montalban
Fatigue in progressive multiple sclerosis is associated with low levels of dehydroepiandrosterone
Multiple Sclerosis, August 1, 2006; 12(4): 487 - 494.
[Abstract] [PDF]


Advertisement